Kwok Edmund S H, Howes Daniel
Department of Emergency Medicine, Queen's University, Kingston, Ontario, Canada.
J Intensive Care Med. 2006 Nov-Dec;21(6):359-63. doi: 10.1177/0885066606290671.
A systematic review of the literature was conducted to determine if the administration of methylene blue in humans improves hemodynamic status and/or outcome in patients with septic shock. Studies were identified from MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials database. The review included human studies of patients with septic shock treated with methylene blue in which hemodynamic variables or mortality rates were reported. An electronic form was used to extract items including study design, population characteristics, intervention details, and outcomes. No meta-analysis was performed. Methylene blue administration in patients with septic shock increases mean arterial pressure and systemic vascular resistance while decreasing vasopressor requirements. Increased pulmonary vascular resistance has been reported with bolus administration but might be avoided by continuous infusion. No other ill effects were reported. Effects on mortality have not been adequately evaluated in the literature.
我们进行了一项系统的文献综述，以确定在人类中使用亚甲蓝是否能改善感染性休克患者的血流动力学状态和/或预后。研究是从MEDLINE、EMBASE和Cochrane对照试验中央注册数据库中识别出来的。该综述纳入了对感染性休克患者使用亚甲蓝治疗的人体研究，这些研究报告了血流动力学变量或死亡率。使用电子表格提取包括研究设计、人群特征、干预细节和结果等项目。未进行荟萃分析。对感染性休克患者使用亚甲蓝可增加平均动脉压和全身血管阻力，同时降低血管升压药的需求量。大剂量给药时曾有肺血管阻力增加的报告，但持续输注可能可避免这种情况。未报告其他不良反应。文献中对死亡率的影响尚未得到充分评估。
